Miruvor
Sign up
The short answer

What studies of red and near-infrared light therapy found

18papers on red and near-infrared light therapy
55people in 2 studies testing red and near-infrared light therapy alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the randomised trial and the placebo trial (very low certainty): 3 of 4 findings are D.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with red and near-infrared light therapy for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 18 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Red and near-infrared light therapy · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Smell and taste loss1 study · 34 people received red and near-infrared light therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (70 in all).

The randomised trial70 randomised · At weeks 7 and 8 · 3 J per spot; 60 J, for 10 min

Smell and taste loss improved more than in the comparison group.

The evidence is very uncertain about the effect of red and near-infrared light therapy on smell and taste loss in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (70 in all)
See the 1 study
  1. Photobiomodulation in the Treatment of Dysgeusia in Patients with Long COVID: A Single-Blind, Randomized Controlled Trial. (2024)

    People in the study
    70 randomised
    Dose
    3 J per spot; 60 J, for 10 min
    Outcome
    improvement scores
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Cognition (brain fog)1 study · 21 people received red and near-infrared light therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 41 people found no clear difference; a small benefit can't be ruled out.

The placebo trial43 randomised · 41 analysed · 8 weeks (56 days · 810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of red and near-infrared light therapy on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 41 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial. (2026)

    People in the study
    43 randomised · 41 analysed
    Dose
    810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks
    Outcome
    Composite cognitive score (all ages) Creyos Research cognitive battery
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Fatigue1 study · 21 people received red and near-infrared light therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 41 people found no clear difference; a small benefit can't be ruled out.

The placebo trial43 randomised · 41 analysed · 8 weeks (56 days · 810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks

No clear difference in fatigue.

The evidence is very uncertain about the effect of red and near-infrared light therapy on fatigue in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 41 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial. (2026)

    People in the study
    43 randomised · 41 analysed
    Dose
    810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks
    Outcome
    Fatigue (FAS total score) Fatigue Assessment Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Quality of life1 study · 21 people received red and near-infrared light therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 41 people found no clear difference; a small benefit can't be ruled out.

The placebo trial43 randomised · 41 analysed · 8 weeks (56 days · 810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks

No clear difference in quality of life.

The evidence is very uncertain about the effect of red and near-infrared light therapy on quality of life in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 41 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial. (2026)

    People in the study
    43 randomised · 41 analysed
    Dose
    810 nm near-infrared light at 40 Hz, 20 min daily, six days per week for 8 weeks
    Outcome
    EQ-5D VAS (overall health) visual analog scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Headache1 study

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial.2026 · placebo trial · 43 randomised · 41 analysed
    Summary

    This randomized, double-blind, sham-controlled pilot trial enrolled 43 adults aged 18–65 in the USA with post-COVID-19 condition cognitive symptoms ≥12 weeks post-infection. Participants received 8 weeks (56 days) of daily 20-min intranasal and transcranial photobiomodulation (itPBM; 810 nm, 40 Hz, six days per week) or sham, followed by a 4-week observation period. There were 23 active and 20 sham participants; 41 were analyzed (21 active, 20 sham). At Day 56, the composite Creyos cognitive score improved by LS mean +0.050 with active itPBM and +0.007 with sham; the between-group difference was 0.043 (95% CI −0.007 to 0.092; p = 0.088). In participants <45 years, active itPBM improved more than sham (difference 0.059, 95% CI 0.007–0.111; p = 0.028); in participants ≥45 years there was no significant difference (p = 0.873). Mobility on EQ-5D-5L favored sham (p = 0.007), and FAS total fatigue showed no significant difference (p = 0.67). No serious adverse events occurred; mild headache was reported in 7/43 (16.3%) and skin irritation in 6/43 (14.0%), and one active participant reported nasal pressure discomfort. Two active participants were excluded from the per-protocol analysis.

  2. Efficacy of the adjunctive use of photobiomodulation therapy in olfactory disorders in post-COVID-19 patients: A randomized controlled trial.2025 · placebo trial · 81 randomised
    Summary

    This single-blinded randomized controlled trial enrolled 81 patients aged 19–59 with persistent olfactory disturbances 1–12 months after SARS-CoV-2 infection, recruited by personal and social media advertisement between January 2021 and October 2022. Patients were allocated to control (n = 27), red light (n = 26), or infrared light (n = 28) groups. All received olfactory training for 10 seconds twice a day for 90 days and prednisolone 40 mg for seven days beginning on the first day of photobiomodulation; photobiomodulation was given twice a week for five weeks, 40 seconds in each nostril. Controls received sham photobiomodulation with the device on but not emitting light; the red-light group received 4 J of red light; the infrared group received infrared photobiomodulation. Outcomes were UPSIT® and subjective smell and taste scores before treatment and at 3 months. Compared with controls, infrared photobiomodulation improved UPSIT® scores by +4.6 points (95% CI 1.5–7.8, p = 0.004); response rates were 26.1% in controls, 43.5% with red light, and 68% with infrared. Red-light UPSIT® change was +2 (−1.3–5.1, p = 0.230). Five, three, and four patients in the control, red, and infrared groups, respectively, did not complete all sessions and were excluded. One patient reported a burning sensation and another reported headache; no major adverse events were reported. The authors note the study was not double-blind and no nasal endoscopy was performed before laser application. They also state it is not known whether PBMT alone can produce the apparent changes.

  3. Using the International Index of Erectile Function-15 in Comparative Analysis Between Transcutaneous Electrical Nerve Stimulation of the Pudendal Nerve and Low-Level Laser Therapy in the Treatment of Erectile Dysfunction After COVID-19.2025 · placebo trial · 82 randomised · 93 started
    Summary

    This interventional single-blind, randomized, four-arm controlled trial compared LLLT, TENS, combined LLLT + TENS, and sham treatment in men with post-COVID-19 erectile dysfunction. The abstract reports 82 patients enrolled; the methods report 93 randomized into four groups (sham, LLLT, TENS, LLLT + TENS). Treatment courses lasted about 38 days, with assessment before treatment, immediately after treatment, and 3 months after treatment. Outcomes included IIEF-15 domains and genital hypoesthesia. Erectile function improved by 38% with LLLT, 27% with TENS, and 64.2% with combined treatment; LLLT exceeded TENS by 8.2%, and combined treatment exceeded LLLT alone by 20%. No notable changes were observed in the control group. Hypoesthesia reduction was 17.2% with LLLT (p = 0.08), 48.7% with TENS, and 60.9% with combined treatment; TENS reduced hypoesthesia 36.9% more than LLLT, and combined treatment added 25% versus TENS. Orgasmic function improved by 69.5% with LLLT and 53.6% with TENS, with 30.5% additional improvement for combined versus LLLT. Sexual desire improved by 72.4% and 50%; intercourse satisfaction by 26.8%, 39.9%, and 56.4%; overall satisfaction by 35.8%, 51.0%, and 79.3%. No side effects were observed after LLLT and TENS procedures. Withdrawals and losses to follow-up were reported per arm.

  4. Evaluation of vascular photobiomodulation for orofacial pain and tension type headache following COVID 19 in a pragmatic randomized clinical trial.2024 · placebo trial · 40 randomised · 34 analysed
    Summary

    This pragmatic double-blind randomized trial evaluated vascular photobiomodulation (VPBM) in post-COVID-19 patients with tension-type headache, orofacial pain, or both persisting for more than 3 months. Patients were recruited at the dental clinic of Nove de Julho University, São Paulo, Brazil. A total of 40 patients were randomized to VPBM or sham VPBM; data analysis and follow-up were conducted for 34 participants who underwent at least two interventions. Treatment was four weeks, once a week, four sessions. VPBM used red light (660 ± 10 nm, 100 mW, 30 min per session) applied transcutaneously over the left radial artery; sham used the same duration with inactive PBM. Outcomes included VAS pain, Brief Pain Inventory, and HIT-6. In the per-protocol analysis, 28 participants underwent the complete intervention (12 VPBM, 16 sham). VAS pain improved in both groups (p < 0.001 VPBM; p = 0.002 sham), and the between-group comparison was p = 0.001, with a greater before-after difference in the VPBM group. In the intention-to-treat VAS analysis, both groups showed reduction but the between-group difference was not significant (p = 0.189). HIT-6 reduction was not statistically significant (final between-group p = 0.770). In the VPBM group, BPI mean pain (p = 0.010), walking (p = 0.011), work (p = 0.009), sleep (p = 0.012), and enjoyment of life (p = 0.016) showed significant within-group reductions. The paper reported no side-effect counts or withdrawals due to harms.

  5. Diode laser in management of loss of taste sensation in patients with post-COVID syndrome: a randomized clinical trial.2023 · placebo trial · 36 randomised
    Summary

    This prospective, randomized (1:1), blinded clinical trial enrolled 36 patients with persistent loss of taste sensation after COVID-19 at the Oral and Maxillofacial Department, Faculty of Dentistry, Fayoum University, from May 2021 to August 2021. Patients received a 940-nm diode laser (1 W continuous wave, handpiece moved over the tongue for two 3-minute intervals separated by a 30-second rest period; 6 min total on tissue) or a placebo light from the same handpiece, 18 per group. Taste was assessed at diagnosis and 1, 2, 3 and 4 weeks post-treatment, and after one month as complete or partial restoration. After one week, 13 (72.2%) in the laser group had restored taste, a significantly higher percentage than the placebo group; after four weeks, 13 (72.2%) in the placebo group had restored taste (p < 0.001). After one month, 17 (94.4%) in the laser group had complete restoration while 7 (38.9%) in the placebo group had partial restoration (p = 0.041; complete restoration p < 0.001). All patients were analyzed; side effects and withdrawals were not reported. The authors state limitations of a young mean age and small sample size, and the paper reports the laser as 940 nm in the methods but 810 nm in the conclusion.

  6. Photobiomodulation in the Treatment of Dysgeusia in Patients with Long COVID: A Single-Blind, Randomized Controlled Trial.2024 · randomised trial · 70 randomised
    Summary

    This single-blind randomized controlled trial asked whether local and systemic photobiomodulation (PBM) improves COVID-19-related dysgeusia in long COVID. Seventy patients with dysgeusia were randomly assigned to active local and systemic PBM (n = 34) or simulated PBM (n = 36). The active group received low-power laser (red wavelength) at 18 spots on the lateral borders of the tongue (3 J per spot), salivary glands (parotid, sublingual, and submandibular glands—3 J per spot), and over the carotid artery for 10 min (60 J). Both groups also received weekly olfactory therapy for up to 8 weeks. The sham group received simulated PBM plus the same olfactory therapy. Dysgeusia improved in both groups. At weeks 7 and 8, improvement scores were significantly higher in the PBM group than in the sham group (p = 0.048). Side effects, harms, and withdrawals were not reported. The provided text does not report the number analysed, and it does not state limitations.

  7. Use of either transcranial or whole-body photobiomodulation treatments improves COVID-19 brain fog.2023 · randomised trial · 16 randomised · 14 analysed
    Summary

    Researchers recruited 16 subjects through word of mouth and social media who had recovered from acute COVID-19 and had cognitive decline (brain fog) of at least 5 months duration. Two separate groups (n = 7 each) received either transcranial photobiomodulation (tPBM) with a 1070 nm helmet or whole-body photobiomodulation (wbPBM) with a 660 and 850 nm light bed, three treatments a week for 4 weeks (12 treatments). The two active treatments were compared; there was no placebo arm. Assessments included MoCA, DSST, trail-making tests A and B, physical reaction time, and a quantitative EEG system (WAVi), pre-treatment Day 1 versus post-treatment Day 12. Fourteen subjects completed all evaluations and treatments; one subject failed to report for testing and treatment, and another withdrew after a single session (inability to participate in repeated treatments and evaluations schedule). No adverse events (anticipated or unanticipated) were encountered during the course of the study. The abstract reports significant improvements in cognitive tests with each device (p < 0.05 and beyond); MoCA was reported as p = 0.052 for both groups. DSST improved with tPBM (p = 0.0028) and wbPBM (p = 0.036); Trail B improved with tPBM (p = 0.0318) and wbPBM (p = 0.043); Trail A improved with tPBM (p = 0.0062) but not wbPBM (p = 0.508); PRT was not significant for either. qEEG showed no difference in effect on delay times or voltages between groups.

  8. Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present.2021 · case report · 1 in the study
    Summary

    This case report described one patient with severe ME/CFS who presented to a rheumatologist’s office in August 2013 after becoming bedridden 4.5 years earlier. Over a 4-year period from September 2013 to August 2017, the patient received a changing protocol that included thyroid medications, antibiotics, antifungals, Hydroxychloroquine, colostrum, kelp, licorice root, fludrocortisone, EFT, EMDR, light therapy, and multiple herbs and supplements. No comparison group was reported. The report described function and symptoms over time. By the Spring of 2014 (~6 months after onset of treatment), she had improved enough to take a college course 1 day/week but was not well enough to drive. By February 2015 she was still predominantly housebound; she was doing better cognitively, but simple activity like walking was still too difficult on most days. She was back at the gym by April 2017 and going for walks daily. In August 2017 she was well enough to move out from her parents’ home and resume graduate school, and she had been stable for at least 6 months. Reported harms included Jarisch–Herxheimer reactions with severe joint and musculoskeletal pain, worsening fatigue, worsening cognitive function, migraines, and drops in blood pressure; doxycycline was discontinued. She also had severe reactions from all supplements, severe discomfort during EFT/EMDR sessions, and could not tolerate blue light more than 1–2 min without severe migraines. The authors stated it was not possible to determine whether improvements were mediated by treatments or spontaneous remission/placebo.

  9. A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up.2022 · combination: given with other treatments · 8 in the study
    Summary

    This standardized case series assessed a combined methylene blue and red-light protocol for COVID-19 disease. Eight pilot subjects with COVID-19 infection were treated in Nassau, Bahamas, over June 2021–August 2021 and followed after a period of one year. There was no comparison group; outcomes were tracked within the same subjects before and after treatment. Treatment included oral methylene blue capsules at 1.5 to 2 mg/kg 12-hourly, later 8-hourly with a maximum dosage of 200 mg; topical 1% methylene blue to oral and nasal cavities activated by a 660 nm LED at 49 J/cm2 for 5 min; and sublingual photobiomodulation at approximately 4.9 J/cm2 for 60 s. Schedules varied. Outcomes included serial PCR cycle threshold measurements, online symptom questionnaires, adverse-effect questionnaires, and a one-year follow-up survey. The paper reports rapid reductions in viral loads and negative PCR tests within a median of 4 days, with significant clinical improvement mostly within 12–24 h. None of the subjects who completed the protocol required in-patient hospitalization, and no significant adverse effects were reported. Six of seven completers reported no long COVID symptoms, recurrence, or subsequent positive SARS-CoV-2 test. Subject five reported long COVID symptoms for 2–3 months, recurrence, and abandoned treatment with nausea; three subjects attended the ER due to dehydration; one had mild throat stinging resolving in less than 30 min. Subject eight reported mild persistent chest congestion.

  10. Effectiveness of physiotherapy modalities on persisting dyspnoea in long COVID: A systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether physiotherapy treatments reduce persisting dyspnoea in long COVID. The reviewers searched MEDLINE, PEDro, WOS, Scopus, VHL and the Cochrane Library for studies published between September 1st, 2019 and July 2nd, 2023; the protocol was registered as CRD42023427464. They included comparative trials of adults with persistent breathlessness following COVID-19, regardless of initial severity, in whom physiotherapy was implemented as treatment for dyspnoea. 19 studies including 1292 adults fulfilled the inclusion criteria. Treatments were grouped as high-intensity rehabilitation, low-to-moderate intensity rehabilitation, respiratory muscle training, and other/passive techniques; dyspnoea was assessed with dyspnoea-specific, functional, or health-related quality-of-life scales. The authors report that physiotherapy and especially pulmonary rehabilitation may help alleviate respiratory symptoms. They state that high-intensity rehabilitation shows particularly more promising results than low-to-moderate rehabilitation or respiratory muscle training, whereas results for low-to-moderate intensity and respiratory muscle training groups were non-significant. For low-level laser therapy, the review states it seems to have significantly reduced dyspnoea and markers of inflammation in people with long-covid. The recorded data include no side-effect, worsening, or withdrawal counts. The authors state limitations including heterogeneity of interventions and controls, risk of bias from open or assessor-only blind studies, and short-term follow-up.

  11. Photobiomodulation in the management of persistent olfactory and gustatory dysfunction post-COVID-19: a systematic review.2025 · systematic review
    Summary

    This systematic review examined photobiomodulation therapy (PBMT) for persistent olfactory and gustatory dysfunction after COVID-19. Searches covered PubMed, SciELO, LILACS, Embase, and the Cochrane Central Register of Controlled Trials from July 2023 to May 2025; ten articles were ultimately included in the qualitative analysis. The included studies assessed intranasal and/or intraoral PBMT, with some using red, infrared, or dual wavelengths; comparators included placebo, sham laser, a control group, and vitamin B complex. Sample sizes in the recorded studies were 20, 1, 14, 36, 10, 1, 70, 50, 6, and 81 patients. Findings included improvement in anosmia after the 7th session and ageusia after the 8th session in one pilot study; VAS scores improving from 4 to 10 after 10 sessions in a case report; complete taste restoration in 94.4% with laser versus partial restoration in 38.9% with placebo in one trial; a dysgeusia reversal rate of 32.35% versus 13.80% at weeks 7–8; and higher taste perception medians of 37/40 in groups G4 and G2 versus 28 in G6. One trial reported no significant differences in olfactory perception between groups except improvement in G4. Reported harms were transient burning sensation and headache during treatment, likely related to olfactory training rather than PBM. Withdrawal counts were not reported. The authors state that the evidence base is limited by small, younger sample sizes, single-center designs, and significant heterogeneity in PBMT devices, laser parameters, and outcomes measures.

  12. Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
    Summary

    This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.

  13. Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
    Summary

    This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.

  14. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.2024 · systematic review
    Summary

    This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.

  15. Effects of rehabilitation interventions for old adults with long COVID: A systematic review and meta-analysis of randomised controlled trials.2024 · systematic review
    Summary

    This systematic review and meta-analysis examined rehabilitation interventions for old adults with long COVID. It searched PubMed, EMBASE, Web of Science, Scopus, and Cochrane Library databases to 15 November 2023 and included 11 RCTs involving 832 participants (64.37 ± 7.94 years; 52.2% were men) with a mean/median age of 60 or older. Rehabilitation interventions included exercise training and respiratory rehabilitation; duration was not reported. They were compared with control groups (usual/standard care/placebo). Outcomes included 6 MWT, 30 seconds STS, HGS, FEV1/FVC, fatigue, quality of life, independence in activities of daily living, depression, and anxiety. Compared with controls, the review reported improvement in 6 MWT (MD = 15.77 m, 95% CI = 5.40, 26.13, P < 0.01), 30 seconds STS (MD = 4.11 n, 95% CI = 2.46, 5.76, P < 0.001), fatigue (SMD = −0.66, 95% CI = −1.13, −0.19, P < 0.01), independence in activities of daily living (SMD = 0.31, 95% CI = 0.13, 0.48, P < 0.001), depression (SMD = −0.89, 95% CI = −1.76, −0.02, P < 0.05), anxiety (SMD = −0.81, 95% CI = −1.58, −0.05, P < 0.05), and all SF-36 quality-of-life domains. HGS was not significant (MD = 1.67 kg, 95% CI = −0.84, 4.18, P > 0.05), and FEV1/FVC was not significant (MD = 3.45%, 95% CI = −1.43%, 8.33%, P > 0.05). Side effects and withdrawals were not reported.

  16. Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis examined treatments for post-COVID-19 olfactory dysfunction. Eleven studies with 1414 participants were included, and six studies with 916 participants were assessed in the meta-analysis. Treatments included intranasal corticosteroids (INCS), oral corticosteroids (OCS), olfactory training (OT), a PEA 700mg/Luteolin 70 mg supplement, intranasal insulin film and intranasal photobiomodulation. Outcomes included VAS, Sniffin' Sticks identification, TDI, CCCRC and recovery time. For INCS+OT versus OT, VAS showed no significant difference (MD 0.89, 95%CI -1.92 to 3.7, p=0.54, 2 RCTs); Sniffin' Sticks identification showed no significant difference at one month (MD 2, 95%CI -0.66 to 4.66, p=0.139) or two months (MD -1, 95%CI -2.83 to 0.83, p=0.281). For OCS+OT versus OT, TDI showed no statistical difference at one month (MD 3.2, 95%CI -0.13 to 6.52, p=0.06) or two months (MD 2.45, 95%CI -3 to 7.89, p=0.38 in 2 case-controlled studies). OT alone showed statistically significant improvement in smell score (MD 4.68, 95%CI 2.65-6.71, p<0.00001). Betamethasone drops had no significant effect on recovery time versus placebo (Hazard ratio 0.88, 95% CI 0.68-1.14; p=0.31). Two studies reported no side effect related to therapy; LeBon and Saussez reported minor OCS side effects, mainly insomnia, headache, and abdominal discomfort. None reported major adverse effects; no side effects related to OT were reported. Authors' stated limitations were short follow-up periods, a small number of well-designed studies, lack of a control group to assess true OT effects, and quality/heterogeneity.

  17. Risk factors and preventive interventions for post Covid-19 condition: systematic review2022 · systematic review
    Summary

    Why: to see whether treatments given during acute or early post-acute Covid-19 prevent post Covid-19 condition (symptoms ≥12 weeks after onset). Who: a systematic review of 31 studies; the searches were run on 28 July 2021 for the intervention question. Several preventive-intervention studies were retrospective controlled cohorts, and most were in hospitalized patients. What was given and compared: corticosteroids, antibiotics, hydroxychloroquine, therapeutic anticoagulation, zinc, intravenous immunoglobulin, oseltamivir, ganciclovir, human umbilical cord mesenchymal stem cells (12 vs 29), an ayurvedic formulation (30 vs 30), Chinese medicine (64 vs 32), telerehabilitation (14 vs 13), cognitive-motor therapy (42), photobiomodulation (5 vs 5), and screening with referrals. Found: certainty was very low throughout. Examples: with stem cells, adverse events were 0 and serious adverse events 0; with the ayurvedic formulation, fatigue was 1 (5%) vs 6 (26.1%); with photobiomodulation, respiratory symptoms were 0/5 (0%) vs 4/5 (80%); with telerehabilitation, adverse events were none reported; with Chinese medicine there was no significant difference in the improvement rates of symptoms, including fatigue, between the two groups (p > .05); antibiotic use was associated with salivary gland ectasia, aOR 8.34 (95% CI, 1.47–158.19).

  18. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime